Omalizumab is known for selectively binding to which immunoglobulin?

Omalizumab is a monoclonal antibody that targets and selectively binds to immunoglobulin E (IgE). IgE is a crucial component in the allergic response, as it is responsible for the mediation of allergic reactions and the activation of mast cells and basophils. By binding to IgE, omalizumab prevents the binding of IgE to its high-affinity receptor (FcεRI) on the surface of mast cells and basophils, thereby inhibiting the release of mediators that contribute to allergic symptoms. This mechanism is particularly beneficial in the treatment of allergic asthma and chronic idiopathic urticaria.

The other immunoglobulins listed, such as IgA, IgM, and IgD, do not have the same role in the allergic response that IgE does. IgA is primarily involved in mucosal immunity, IgM is the first antibody produced in response to an infection, and IgD plays a role in B cell activation. None of these immunoglobulins are targets for omalizumab. Thus, the specificity of omalizumab for IgE underscores its therapeutic use in managing allergic conditions.